跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
The Long, Expensive Road of Clinical Trials

The Hardest Resource to Find Is People

2 / 4
Think about why eligibility criteria exist. They reduce noise, so a real effect is easier to see. But that same filtering shrinks the pool of people who can join. Then a second filter applies: can those people actually get to a site, and are they willing to accept the chance of a placebo? Many never hear about the trial at all. Now add the retention problem. Even a trial that enrolls well can lose participants to side effects, travel burden, or simple life changes. When enough people leave, the trial becomes underpowered. That does not mean the drug failed; it means the trial could not tell whether it worked. So recruitment and retention are not administrative details. They set the pace of the entire program, and they depend on human circumstances that no design tool can optimize.
0:00 / 0:00

Eligibility criteria narrow the pool for scientific reasons, but the pool is then narrowed again by reachability, willingness, and the burden of participation. Retention adds a second filter: participants who leave reduce the trial's ability to detect a real effect.

What limits enrollment and retention

  • Narrow eligibility criteria: specific disease stage, prior treatments, age range, and excluded conditions
  • Limited sites: participants may need repeated travel to a research center
  • Awareness: many eligible patients never learn a trial exists
  • Willingness: some decline the chance of placebo or an unproven treatment
  • Dropout: side effects, inconvenience, relocation, or loss of interest reduce the final analyzable group

A trial that loses too many participants can become underpowered: it may fail to show a real benefit simply because too few people remained to measure it. The result is not 'the drug does not work' but 'this trial could not tell.'

上一页2 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion